Novo Nordisk Stock Slumps 30% This Year After Morgan Stanley Downgrade
Concerns Over Weight-Loss Drugs and Alzheimer’s Treatment Weigh on Novo Nordisk Stock
Morgan Stanley analysts have downgraded Novo Nordisk’s stock, citing concerns over falling sales of weight-loss drugs Ozempic and Wegovy, as well as doubts about the effectiveness of the company’s experimental treatment for Alzheimer’s disease.
Novo Nordisk’s Stock Slides Following Morgan Stanley Downgrade
U.S.-listed shares of Novo Nordisk (NVO) have slid in recent trading following a downgrade from Morgan Stanley, which raised concerns about demand for the company’s GLP-1 drugs Ozempic and Wegovy, as well as their effectiveness in fighting Alzheimer’s disease. The bank dropped its rating to "underweight" from "equal weight," and lowered the price target to $47 from $59. The stock was recently down less than 1% to below $55, slightly extending year-to-date declines.
Concerns Over Demand for Weight-Loss Drugs
Morgan Stanley has expressed concerns over the demand for Ozempic and Wegovy, citing stagnating prescriptions in the US and a forecasted decline in the US GLP-1 diabetes franchise in 2026 due to market share and price pressure. The analysts also expect Ozempic’s growth ex-US to be impacted by the first generic competition in Canada and emerging markets.
Alzheimer’s Treatment Trials May Disappoint
The analysts believe that the results of trials of Novo Nordisk’s GLP-1 treatments for Alzheimer’s disease coming in the next few weeks will likely fall short of showing statistically significant outcomes. This has raised doubts about the effectiveness of the company’s experimental treatment, which is still in its trial phase.
Doubts Over Potential Price Cuts and Competition
Morgan Stanley has also warned about the downside risks of potential price cuts for Ozempic and Wegovy in Medicare Part D plans, as well as doubts about Novo Nordisk’s experimental obesity/diabetes combination drug CagriSemi outperforming rival Eli Lilly’s (LLY) Zepbound. The analysts believe that these factors will continue to weigh on the company’s stock price.
Year-Over-Year Declines
U.S.-listed shares of Novo Nordisk have lost a third of their value this year, making the Morgan Stanley downgrade and price target reduction even more significant. As the company continues to face challenges in the market, analysts will be closely watching its next moves.
Impact on Investors
The concerns expressed by Morgan Stanley over demand for weight-loss drugs and Alzheimer’s treatment effectiveness have left investors wondering about the future prospects of Novo Nordisk’s stock. With a price target reduction and an "underweight" rating, it is clear that the analysts are uncertain about the company’s ability to meet its growth expectations.
Conclusion
The Morgan Stanley downgrade and price target reduction for Novo Nordisk’s stock have sent shockwaves through the market, casting doubts over the demand for the company’s weight-loss drugs and Alzheimer’s treatment effectiveness. As investors continue to monitor the situation, it remains to be seen how Novo Nordisk will respond to these concerns and what impact this will have on its long-term prospects.
Morgan Stanley analysts have issued a stern warning about Novo Nordisk’s stock performance, citing stagnating demand for weight-loss medications Ozempic and Wegovy and doubts over the results of recent Alzheimer’s disease trials. The downgrade comes as U.S.-listed shares of the company are already trading lower by more than 30% year-over-year.
